{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T13:53:29Z","timestamp":1775915609816,"version":"3.50.1"},"publisher-location":"Cham","reference-count":83,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030573683","type":"print"},{"value":"9783030573690","type":"electronic"}],"license":[{"start":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T00:00:00Z","timestamp":1608249600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T00:00:00Z","timestamp":1608249600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1007\/978-3-030-57369-0_6","type":"book-chapter","created":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T09:26:59Z","timestamp":1608197219000},"page":"81-92","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Recent Advances in the Potential of Cannabinoids for Neuroprotection in Alzheimer\u2019s, Parkinson\u2019s, and Huntington\u2019s Diseases"],"prefix":"10.1007","author":[{"given":"Catalina","family":"P\u00e9rez-Olives","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Rivas-Santisteban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaume","family":"Lillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gemma","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Franco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,12,18]]},"reference":[{"key":"6_CR1","doi-asserted-by":"publisher","first-page":"903","DOI":"10.3233\/JAD-160533","volume":"54","author":"E Aso","year":"2016","unstructured":"Aso E, Andr\u00e9s-Benito P, Ferrer I (2016) Delineating the efficacy of a cannabis-based medicine at advanced stages of dementia in a murine model. J Alzheimers Dis 54:903\u2013912. https:\/\/doi.org\/10.3233\/JAD-160533","journal-title":"J Alzheimers Dis"},{"key":"6_CR2","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1111\/bph.14564","volume":"176","author":"B Attili","year":"2019","unstructured":"Attili B, Celen S, Ahamed M, Koole M, Van Den Haute C, Vanduffel W, Bormans G (2019) Preclinical evaluation of [18 F]MA3: a CB2 receptor agonist radiotracer for PET. Br J Pharmacol 176:1481\u20131491. https:\/\/doi.org\/10.1111\/bph.14564","journal-title":"Br J Pharmacol"},{"key":"6_CR3","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/978-1-4939-7825-0_25","volume-title":"Methods in molecular biology","author":"AM Bagher","year":"2018","unstructured":"Bagher AM, Laprairie RB, Kelly MEM, Denovan-Wright EM (2018) Methods to quantify cell signaling and GPCR receptor ligand bias: characterization of drugs that target the Endocannabinoid receptors in Huntington\u2019s disease. In: Methods in molecular biology. Humana Press, Clifton, N.J, pp 549\u2013571. https:\/\/doi.org\/10.1007\/978-1-4939-7825-0_25"},{"key":"6_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/bph.12850","volume":"171","author":"NA Balenga","year":"2014","unstructured":"Balenga NA, Mart\u00ednez-Pinilla E, Kargl J, Schr\u00f6der R, Peinhaupt M, Platzer W, B\u00e1lint Z, Zamarbide M, Dopeso-Reyes IG, Ricobaraza A et al (2014) Heteromerization of GPR55 and cannabinoid CB2 receptors modulates signalling. Br J Pharmacol 171:1\u201364. https:\/\/doi.org\/10.1111\/bph.12850","journal-title":"Br J Pharmacol"},{"key":"6_CR5","doi-asserted-by":"publisher","first-page":"11136","DOI":"10.1523\/JNEUROSCI.23-35-11136.2003","volume":"23","author":"C Benito","year":"2003","unstructured":"Benito C, N\u00fa\u00f1ez E, Tol\u00f3n RM, Carrier EJ, R\u00e1bano A, Hillard CJ, Romero J (2003) Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer\u2019s disease brains. J Neurosci 23:11136\u201311141","journal-title":"J Neurosci"},{"key":"6_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.lfs.2018.11.058","volume":"217","author":"M \u00c7ak\u0131r","year":"2019","unstructured":"\u00c7ak\u0131r M, Tekin S, Do\u011fanyi\u011fit Z, Erden Y, Soyt\u00fcrk M, \u00c7i\u011fremi\u015f Y, Sandal S (2019) Cannabinoid type 2 receptor agonist JWH-133, attenuates Okadaic acid induced spatial memory impairment and neurodegeneration in rats. Life Sci 217:25\u201333. https:\/\/doi.org\/10.1016\/j.lfs.2018.11.058","journal-title":"Life Sci"},{"key":"6_CR7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1191\/0960327102ht217oa","volume":"21","author":"EJ Calabrese","year":"2002","unstructured":"Calabrese EJ, Baldwin LA (2002) Defining hormesis. Hum Exp Toxicol 21:91\u201397. https:\/\/doi.org\/10.1191\/0960327102ht217oa","journal-title":"Hum Exp Toxicol"},{"key":"6_CR8","doi-asserted-by":"publisher","DOI":"10.1111\/eci.12920","volume":"48","author":"EJ Calabrese","year":"2018","unstructured":"Calabrese EJ, Rubio-Casillas A (2018) Biphasic effects of THC in memory and cognition. Eur J Clin Investig 48:e12920. https:\/\/doi.org\/10.1111\/eci.12920","journal-title":"Eur J Clin Investig"},{"key":"6_CR9","doi-asserted-by":"publisher","first-page":"20851","DOI":"10.1074\/jbc.M111.335273","volume":"287","author":"L Call\u00e9n","year":"2012","unstructured":"Call\u00e9n L, Moreno E, Barroso-Chinea P, Moreno-Delgado D, Cort\u00e9s A, Mallol J, Casad\u00f3 V, Lanciego JL, Franco R, Lluis C et al (2012) Cannabinoid receptors CB1 and CB2 form functional heteromers in brain. J Biol Chem 287:20851\u201320865. https:\/\/doi.org\/10.1074\/jbc.M111.335273","journal-title":"J Biol Chem"},{"key":"6_CR10","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1527-3458.2006.00091.x","volume":"12","author":"MAM Carai","year":"2006","unstructured":"Carai MAM, Colombo G, Maccioni P, Gessa GL (2006) Efficacy of rimonabant and other cannabinoid CB1 receptor antagonists in reducing food intake and body weight: preclinical and clinical data. CNS Drug Rev 12:91\u201399. https:\/\/doi.org\/10.1111\/j.1527-3458.2006.00091.x","journal-title":"CNS Drug Rev"},{"key":"6_CR11","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.bbi.2016.06.010","volume":"57","author":"M Celorrio","year":"2016","unstructured":"Celorrio M, Fern\u00e1ndez-Su\u00e1rez D, Rojo-Bustamante E, Echeverry-Alzate V, Ram\u00edrez MJ, Hillard CJ, L\u00f3pez-Moreno JA, Maldonado R, Oyarz\u00e1bal J, Franco R et al (2016) Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson\u2019s disease. Brain Behav Immun 57:94\u2013105. https:\/\/doi.org\/10.1016\/j.bbi.2016.06.010","journal-title":"Brain Behav Immun"},{"key":"6_CR12","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.neuropharm.2017.08.017","volume":"125","author":"M Celorrio","year":"2017","unstructured":"Celorrio M, Rojo-Bustamante E, Fern\u00e1ndez-Su\u00e1rez D, S\u00e1ez E, Estella-Hermoso de Mendoza A, M\u00fcller CE, Ram\u00edrez MJ, Oyarz\u00e1bal J, Franco R, Aymerich MS (2017) GPR55: a therapeutic target for Parkinson\u2019s disease? Neuropharmacology 125:319\u2013332. https:\/\/doi.org\/10.1016\/j.neuropharm.2017.08.017","journal-title":"Neuropharmacology"},{"key":"6_CR13","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/bs.irn.2018.08.004","volume":"141","author":"R Cilia","year":"2018","unstructured":"Cilia R (2018) Molecular imaging of the cannabinoid system in idiopathic Parkinson\u2019s disease. Int Rev Neurobiol 141:305\u2013345. https:\/\/doi.org\/10.1016\/bs.irn.2018.08.004","journal-title":"Int Rev Neurobiol"},{"key":"6_CR14","doi-asserted-by":"publisher","first-page":"29789","DOI":"10.1038\/srep29789","volume":"6","author":"J D\u00edaz-Alonso","year":"2016","unstructured":"D\u00edaz-Alonso J, Para\u00edso-Luna J, Navarrete C, del R\u00edo C, Cantarero I, Palomares B, Aguareles J, Fern\u00e1ndez-Ruiz J, Bellido ML, Pollastro F et al (2016) VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington\u2019s disease. Sci Rep 6:29789. https:\/\/doi.org\/10.1038\/srep29789","journal-title":"Sci Rep"},{"key":"6_CR15","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/978-3-319-20825-1_8","volume":"231","author":"J Fern\u00e1ndez-Ruiz","year":"2015","unstructured":"Fern\u00e1ndez-Ruiz J, Romero J, Ramos JA (2015) Endocannabinoids and neurodegenerative disorders: Parkinson\u2019s disease, Huntington\u2019s chorea, Alzheimer\u2019s disease, and others. Handb Exp Pharmacol 231:233\u2013259. https:\/\/doi.org\/10.1007\/978-3-319-20825-1_8","journal-title":"Handb Exp Pharmacol"},{"key":"6_CR16","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1007\/s40265-018-0996-1","volume":"78","author":"AI Fraguas-S\u00e1nchez","year":"2018","unstructured":"Fraguas-S\u00e1nchez AI, Torres-Su\u00e1rez AI (2018) Medical use of cannabinoids. Drugs 78:1665\u20131703. https:\/\/doi.org\/10.1007\/s40265-018-0996-1","journal-title":"Drugs"},{"key":"6_CR17","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1515\/bmc-2018-0013","volume":"9","author":"R Franco","year":"2018","unstructured":"Franco R, Aguinaga D, Jim\u00e9nez J, Lillo J, Mart\u00ednez-Pinilla E, Navarro G (2018) Biased receptor functionality versus biased agonism in G-protein-coupled receptors. Biomol Concepts 9:143\u2013154. https:\/\/doi.org\/10.1515\/bmc-2018-0013","journal-title":"Biomol Concepts"},{"key":"6_CR18","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3389\/fphar.2014.00146","volume":"5","author":"R Franco","year":"2014","unstructured":"Franco R, Cedazo-Minguez A (2014) Successful therapies for Alzheimer\u2019s disease: why so many in animal models and none in humans? Front Pharmacol 5:146. https:\/\/doi.org\/10.3389\/fphar.2014.00146","journal-title":"Front Pharmacol"},{"key":"6_CR19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.pneurobio.2015.05.003","volume":"131","author":"R Franco","year":"2015","unstructured":"Franco R, Fern\u00e1ndez-Su\u00e1rez D (2015) Alternatively activated microglia and macrophages in the central nervous system. Prog Neurobiol 131:65\u201386. https:\/\/doi.org\/10.1016\/j.pneurobio.2015.05.003","journal-title":"Prog Neurobiol"},{"key":"6_CR20","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1080\/17460441.2019.1581169","volume":"14","author":"R Franco","year":"2019","unstructured":"Franco R, Mart\u00ednez-Pinilla E, Navarro G (2019) Why have transgenic rodent models failed to successfully mimic Alzheimer\u2019s disease. How can we develop effective drugs without them? Expert Opin Drug Discovery 14:327\u2013330. https:\/\/doi.org\/10.1080\/17460441.2019.1581169","journal-title":"Expert Opin Drug Discovery"},{"key":"6_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fpsyt.2018.00068","volume":"9","author":"R Franco","year":"2018","unstructured":"Franco R, Navarro G (2018) Adenosine A2A receptor antagonists in neurodegenerative diseases: huge potential and huge challenges. Front Psych 9:1\u20135. https:\/\/doi.org\/10.3389\/fpsyt.2018.00068","journal-title":"Front Psych"},{"key":"6_CR22","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/glia.23080","volume":"65","author":"R Gajardo-G\u00f3mez","year":"2017","unstructured":"Gajardo-G\u00f3mez R, Labra VC, Maturana CJ, Shoji KF, Santiba\u00f1ez CA, S\u00e1ez JC, Giaume C, Orellana JA (2017) Cannabinoids prevent the amyloid \u03b2-induced activation of astroglial hemichannels: a neuroprotective mechanism. Glia 65:122\u2013137. https:\/\/doi.org\/10.1002\/glia.23080","journal-title":"Glia"},{"key":"6_CR23","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1021\/ja01062a046","volume":"86","author":"Y Gaoni","year":"1964","unstructured":"Gaoni Y, Mechoulam R (1964) Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc 86:1646\u20131647. https:\/\/doi.org\/10.1021\/ja01062a046","journal-title":"J Am Chem Soc"},{"key":"6_CR24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12974-018-1060-5","volume":"15","author":"C Garc\u00eda","year":"2018","unstructured":"Garc\u00eda C, G\u00f3mez-Ca\u00f1as M, Burgaz S, Palomares B, G\u00f3mez-G\u00e1lvez Y, Palomo-Garo C, Campo S, Ferrer-Hern\u00e1ndez J, Pavicic C, Navarrete C et al (2018) Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson\u2019s disease: possible involvement of different binding sites at the PPAR\u03b3 receptor. J Neuroinflammation 15:19. https:\/\/doi.org\/10.1186\/s12974-018-1060-5","journal-title":"J Neuroinflammation"},{"key":"6_CR25","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1007\/s13311-018-0610-y","volume":"15","author":"MS Garc\u00eda-Guti\u00e9rrez","year":"2018","unstructured":"Garc\u00eda-Guti\u00e9rrez MS, Navarrete F, Navarro G, Reyes-Resina I, Franco R, Lanciego JL, Giner S, Manzanares J (2018) Alterations in gene and Protein expression of cannabinoid CB2 and GPR55 receptors in the dorsolateral prefrontal cortex of suicide victims. Neurotherapeutics 15:796\u2013806. https:\/\/doi.org\/10.1007\/s13311-018-0610-y","journal-title":"Neurotherapeutics"},{"key":"6_CR26","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.pnpbp.2015.03.017","volume":"64","author":"Y G\u00f3mez-G\u00e1lvez","year":"2016","unstructured":"G\u00f3mez-G\u00e1lvez Y, Palomo-Garo C, Fern\u00e1ndez-Ruiz J, Garc\u00eda C (2016) Potential of the cannabinoid CB2 receptor as a pharmacological target against inflammation in Parkinson\u2019s disease. Prog Neuro-Psychopharmacol Biol Psychiatry 64:200\u2013208. https:\/\/doi.org\/10.1016\/j.pnpbp.2015.03.017","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"6_CR27","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3389\/fnmol.2019.00094","volume":"12","author":"M G\u00f3mez-Ruiz","year":"2019","unstructured":"G\u00f3mez-Ruiz M, Rodr\u00edguez-Cueto C, Luna-Pi\u00f1el E, Hern\u00e1ndez-G\u00e1lvez M, Fern\u00e1ndez-Ruiz J (2019) Endocannabinoid system in Spinocerebellar ataxia Type-3 and other autosomal-dominant cerebellar ataxias: potential role in pathogenesis and expected relevance as Neuroprotective targets. Front Mol Neurosci 12:94. https:\/\/doi.org\/10.3389\/fnmol.2019.00094","journal-title":"Front Mol Neurosci"},{"key":"6_CR28","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.mcn.2008.05.001","volume":"38","author":"MB Goncalves","year":"2008","unstructured":"Goncalves MB, Suetterlin P, Yip P, Molina-Holgado F, Walker DJ, Oudin MJ, Zentar MP, Pollard S, Y\u00e1\u00f1ez-Mu\u00f1oz RJ, Williams G et al (2008) A diacylglycerol lipase-CB2 cannabinoid pathway regulates adult subventricular zone neurogenesis in an age-dependent manner. Mol Cell Neurosci 38:526\u2013536. https:\/\/doi.org\/10.1016\/j.mcn.2008.05.001","journal-title":"Mol Cell Neurosci"},{"key":"6_CR29","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ejmech.2019.01.030","volume":"166","author":"P Gonz\u00e1lez-Naranjo","year":"2019","unstructured":"Gonz\u00e1lez-Naranjo P, P\u00e9rez-Macias N, P\u00e9rez C, Roca C, Vaca G, Gir\u00f3n R, S\u00e1nchez-Robles E, Mart\u00edn-Fontelles MI, de Ceballos ML, Martin-Requero A et al (2019) Indazolylketones as new multitarget cannabinoid drugs. Eur J Med Chem 166:90\u2013107. https:\/\/doi.org\/10.1016\/j.ejmech.2019.01.030","journal-title":"Eur J Med Chem"},{"key":"6_CR30","doi-asserted-by":"publisher","first-page":"607","DOI":"10.3390\/molecules23030607","volume":"23","author":"B Janssen","year":"2018","unstructured":"Janssen B, Vugts D, Windhorst A, Mach R (2018) PET imaging of microglial activation\u2014beyond targeting TSPO. Molecules 23:607. https:\/\/doi.org\/10.3390\/molecules23030607","journal-title":"Molecules"},{"key":"6_CR31","doi-asserted-by":"publisher","first-page":"5086","DOI":"10.1039\/c9ob00656g","volume":"17","author":"A Kallinen","year":"2019","unstructured":"Kallinen A, Boyd R, Lane S, Bhalla R, Mardon K, Stimson DHR, Werry EL, Fulton R, Connor M, Kassiou M (2019) Synthesis and in vitro evaluation of fluorine-18 benzimidazole sulfones as CB2 PET-radioligands. Org Biomol Chem 17:5086\u20135098. https:\/\/doi.org\/10.1039\/c9ob00656g","journal-title":"Org Biomol Chem"},{"key":"6_CR32","doi-asserted-by":"publisher","first-page":"44234","DOI":"10.1074\/jbc.M112.364109","volume":"287","author":"J Kargl","year":"2012","unstructured":"Kargl J, Balenga N, Parzmair GP, Brown AJ, Heinemann A, Waldhoer M (2012) The cannabinoid receptor CB1 modulates the signaling properties of the lysophosphatidylinositol receptor GPR55. J Biol Chem 287:44234\u201344248. https:\/\/doi.org\/10.1074\/jbc.M112.364109","journal-title":"J Biol Chem"},{"key":"6_CR33","first-page":"71","volume":"19","author":"I Katz","year":"2017","unstructured":"Katz I, Katz D, Shoenfeld Y, Porat-Katz BS (2017) Clinical evidence for utilizing cannabinoids in the elderly. Isr Med Assoc J IMAJ 19:71\u201375","journal-title":"Isr Med Assoc J IMAJ"},{"key":"6_CR34","doi-asserted-by":"publisher","first-page":"252","DOI":"10.2174\/1574887113666180521093529","volume":"13","author":"RJ Kaur","year":"2018","unstructured":"Kaur RJ, Singh S, Sidhu P, Sharma PK (2018) TGN-1412 and BIA-2474 trials with tragic end: lessons learnt to make clinical trials safer. Rev Recent Clin Trials 13:252\u2013256. https:\/\/doi.org\/10.2174\/1574887113666180521093529","journal-title":"Rev Recent Clin Trials"},{"key":"6_CR35","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/bs.apha.2017.03.009","volume":"80","author":"DT Kho","year":"2017","unstructured":"Kho DT, Glass M, Graham ES (2017) Is the cannabinoid CB 2 receptor a major regulator of the Neuroinflammatory Axis of the neurovascular unit in humans? Adv Pharmacol 80:367\u2013396. https:\/\/doi.org\/10.1016\/bs.apha.2017.03.009","journal-title":"Adv Pharmacol"},{"key":"6_CR36","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1111\/bph.13250","volume":"172","author":"RB Laprairie","year":"2015","unstructured":"Laprairie RB, Bagher AM, Kelly MEM, Denovan-Wright EM (2015) Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol 172:4790\u20134805. https:\/\/doi.org\/10.1111\/bph.13250","journal-title":"Br J Pharmacol"},{"key":"6_CR37","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1124\/mol.115.101980","volume":"89","author":"RB Laprairie","year":"2016","unstructured":"Laprairie RB, Bagher AM, Kelly MEM, Denovan-Wright EM (2016) Biased type 1 cannabinoid receptor signaling influences neuronal viability in a cell culture model of Huntington disease. Mol Pharmacol 89:364\u2013375. https:\/\/doi.org\/10.1124\/mol.115.101980","journal-title":"Mol Pharmacol"},{"key":"6_CR38","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/s41401-018-0031-9","volume":"40","author":"AS Laun","year":"2019","unstructured":"Laun AS, Shrader SH, Brown KJ, Song Z-H (2019) GPR3, GPR6, and GPR12 as novel molecular targets: their biological functions and interaction with cannabidiol. Acta Pharmacol Sin 40:300\u2013308. https:\/\/doi.org\/10.1038\/s41401-018-0031-9","journal-title":"Acta Pharmacol Sin"},{"key":"6_CR39","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.bbrc.2017.05.165","volume":"490","author":"AS Laun","year":"2017","unstructured":"Laun AS, Song Z-H (2017) GPR3 and GPR6, novel molecular targets for cannabidiol. Biochem Biophys Res Commun 490:17\u201321. https:\/\/doi.org\/10.1016\/j.bbrc.2017.05.165","journal-title":"Biochem Biophys Res Commun"},{"key":"6_CR40","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/ijms18010026","volume":"18","author":"R Libro","year":"2016","unstructured":"Libro R, Diomede F, Scionti D, Piattelli A, Grassi G, Pollastro F, Bramanti P, Mazzon E, Trubiani O (2016) Cannabidiol modulates the expression of Alzheimer\u2019s disease-related genes in Mesenchymal stem cells. Int J Mol Sci 18:26. https:\/\/doi.org\/10.3390\/ijms18010026","journal-title":"Int J Mol Sci"},{"key":"6_CR41","doi-asserted-by":"publisher","first-page":"301","DOI":"10.9758\/cpn.2017.15.4.301","volume":"15","author":"K Lim","year":"2017","unstructured":"Lim K, See YM, Lee J (2017) A systematic review of the effectiveness of medical cannabis for psychiatric, movement and neurodegenerative disorders. Clin Psychopharmacol Neurosci 15:301\u2013312. https:\/\/doi.org\/10.9758\/cpn.2017.15.4.301","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"6_CR42","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s40263-015-0270-y","volume":"29","author":"CS Liu","year":"2015","unstructured":"Liu CS, Chau SA, Ruthirakuhan M, Lanct\u00f4t KL, Herrmann N (2015) Cannabinoids for the treatment of agitation and aggression in Alzheimer\u2019s disease. CNS Drugs 29:615\u2013623. https:\/\/doi.org\/10.1007\/s40263-015-0270-y","journal-title":"CNS Drugs"},{"key":"6_CR43","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3233\/JAD-180137","volume":"64","author":"A Llorente-Ovejero","year":"2018","unstructured":"Llorente-Ovejero A, Manuel I, Lombardero L, Giralt MT, Ledent C, Gim\u00e9nez-Llort L, Rodr\u00edguez-Puertas R (2018) Endocannabinoid and muscarinic signaling crosstalk in the 3xTg-AD mouse model of Alzheimer\u2019s disease. J Alzheimers Dis 64:117\u2013136. https:\/\/doi.org\/10.3233\/JAD-180137","journal-title":"J Alzheimers Dis"},{"key":"6_CR44","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1007\/s00415-016-8145-9","volume":"263","author":"JL L\u00f3pez-Send\u00f3n Moreno","year":"2016","unstructured":"L\u00f3pez-Send\u00f3n Moreno JL, Garc\u00eda Caldentey J, Trigo Cubillo P, Ruiz Romero C, Garc\u00eda Ribas G, Alonso Arias MAA, Garc\u00eda de Y\u00e9benes MJ, Tol\u00f3n RM, Galve-Roperh I, Sagredo O et al (2016) A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington\u2019s disease. J Neurol 263:1390\u20131400. https:\/\/doi.org\/10.1007\/s00415-016-8145-9","journal-title":"J Neurol"},{"key":"6_CR45","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejim.2018.01.004","volume":"49","author":"CA MacCallum","year":"2018","unstructured":"MacCallum CA, Russo EB (2018) Practical considerations in medical cannabis administration and dosing. Eur J Intern Med 49:12\u201319. https:\/\/doi.org\/10.1016\/j.ejim.2018.01.004","journal-title":"Eur J Intern Med"},{"key":"6_CR46","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1080\/17512433.2017.1292849","volume":"10","author":"M Maccarrone","year":"2017","unstructured":"Maccarrone M, Maldonado R, Casas M, Henze T, Centonze D (2017) Cannabinoids therapeutic use: what is our current understanding following the introduction of THC, THC:CBD oromucosal spray and others? Expert Rev Clin Pharmacol 10:443\u2013455. https:\/\/doi.org\/10.1080\/17512433.2017.1292849","journal-title":"Expert Rev Clin Pharmacol"},{"key":"6_CR47","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.neuropharm.2015.10.021","volume":"101","author":"G Madeo","year":"2016","unstructured":"Madeo G, Schirinzi T, Maltese M, Martella G, Rapino C, Fezza F, Mastrangelo N, Bonsi P, Maccarrone M, Pisani A (2016) Dopamine-dependent CB 1 receptor dysfunction at corticostriatal synapses in homozygous PINK1 knockout mice. Neuropharmacology 101:460\u2013470. https:\/\/doi.org\/10.1016\/j.neuropharm.2015.10.021","journal-title":"Neuropharmacology"},{"key":"6_CR48","doi-asserted-by":"publisher","first-page":"541","DOI":"10.2174\/1871527316666170413114210","volume":"16","author":"C Mannucci","year":"2017","unstructured":"Mannucci C, Navarra M, Calapai F, Spagnolo EV, Busard\u00f2 FP, Cas RD, Ippolito FM, Calapai G (2017) Neurological aspects of medical use of Cannabidiol. CNS Neurol Disord Drug Targets 16:541\u2013553. https:\/\/doi.org\/10.2174\/1871527316666170413114210","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"6_CR49","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.expneurol.2014.06.017","volume":"261","author":"E Mart\u00ednez-Pinilla","year":"2014","unstructured":"Mart\u00ednez-Pinilla E, Reyes-Resina I, O\u00f1atibia-Astibia A, Zamarbide M, Ricobaraza A, Navarro G, Moreno E, Dopeso-Reyes IGG, Sierra S, Rico AJJ et al (2014) CB1 and GPR55 receptors are co-expressed and form heteromers in rat and monkey striatum. Exp Neurol 261:44\u201352. https:\/\/doi.org\/10.1016\/j.expneurol.2014.06.017","journal-title":"Exp Neurol"},{"key":"6_CR50","doi-asserted-by":"publisher","first-page":"744","DOI":"10.3389\/fphar.2017.00744","volume":"8","author":"E Mart\u00ednez-Pinilla","year":"2017","unstructured":"Mart\u00ednez-Pinilla E, Varani K, Reyes-Resina I, Angelats E, Vincenzi F, Ferreiro-Vera C, Oyarzabal J, Canela EI, Lanciego JL, Nadal X et al (2017) Binding and signaling studies disclose a potential allosteric site for cannabidiol in cannabinoid CB2receptors. Front Pharmacol 8:744. https:\/\/doi.org\/10.3389\/fphar.2017.00744","journal-title":"Front Pharmacol"},{"key":"6_CR51","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12974-016-0484-z","volume":"13","author":"RC McCarthy","year":"2016","unstructured":"McCarthy RC, Lu D-Y, Alkhateeb A, Gardeck AM, Lee C-H, Wessling-Resnick M (2016) Characterization of a novel adult murine immortalized microglial cell line and its activation by amyloid-beta. J Neuroinflammation 13:21. https:\/\/doi.org\/10.1186\/s12974-016-0484-z","journal-title":"J Neuroinflammation"},{"key":"6_CR52","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1146\/annurev-psych-113011-143739","volume":"64","author":"R Mechoulam","year":"2013","unstructured":"Mechoulam R, Parker LA (2013) The Endocannabinoid system and the brain. Annu Rev Psychol 64:21\u201347. https:\/\/doi.org\/10.1146\/annurev-psych-113011-143739","journal-title":"Annu Rev Psychol"},{"key":"6_CR53","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1126\/science.169.3945.611","volume":"169","author":"R Mechoulam","year":"1970","unstructured":"Mechoulam R, Shani A, Edery H, Grunfeld Y (1970) Chemical basis of hashish activity. Science (New York, NY) 169:611\u2013612. https:\/\/doi.org\/10.1126\/science.169.3945.611","journal-title":"Science (New York, NY)"},{"key":"6_CR54","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1080\/03602532.2018.1428616","volume":"50","author":"P Morales","year":"2018","unstructured":"Morales P, Isawi I, Reggio PH (2018) Towards a better understanding of the cannabinoid-related orphan receptors GPR3, GPR6, and GPR12. Drug Metab Rev 50:74\u201393. https:\/\/doi.org\/10.1080\/03602532.2018.1428616","journal-title":"Drug Metab Rev"},{"key":"6_CR55","doi-asserted-by":"publisher","first-page":"4263","DOI":"10.1111\/bph.14019","volume":"174","author":"X Nadal","year":"2017","unstructured":"Nadal X, del R\u00edo C, Casano S, Palomares B, Ferreiro-Vera C, Navarrete C, S\u00e1nchez-Carnerero C, Cantarero I, Bellido ML, Meyer S et al (2017) Tetrahydrocannabinolic acid is a potent PPAR\u03b3 agonist with neuroprotective activity. Br J Pharmacol 174:4263\u20134276. https:\/\/doi.org\/10.1111\/bph.14019","journal-title":"Br J Pharmacol"},{"key":"6_CR56","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.bbi.2017.08.015","volume":"67","author":"G Navarro","year":"2018","unstructured":"Navarro G, Borroto-Escuela D, Angelats E, Etayo I, Reyes-Resina I, Pulido-Salgado M, Rodr\u00edguez-P\u00e9rez A, Canela E, Saura J, Lanciego JL et al (2018) Receptor-heteromer mediated regulation of endocannabinoid signaling in activated microglia. Role of CB1 and CB2 receptors and relevance for Alzheimer\u2019s disease and levodopa-induced dyskinesia. Brain Behav Immun 67:139\u2013151. https:\/\/doi.org\/10.1016\/j.bbi.2017.08.015","journal-title":"Brain Behav Immun"},{"key":"6_CR57","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.bcp.2018.08.046","volume":"157","author":"G Navarro","year":"2018","unstructured":"Navarro G, Reyes-Resina I, Rivas-Santisteban R, S\u00e1nchez de Medina V, Morales P, Casano S, Ferreiro-Vera C, Lillo A, Aguinaga D, Jagerovic N et al (2018) Cannabidiol skews biased agonism at cannabinoid CB1 and CB2 receptors with smaller effect in CB1-CB2 heteroreceptor complexes. Biochem Pharmacol 157:148\u2013158. https:\/\/doi.org\/10.1016\/j.bcp.2018.08.046","journal-title":"Biochem Pharmacol"},{"key":"6_CR58","doi-asserted-by":"publisher","first-page":"632","DOI":"10.3389\/fphar.2018.00632","volume":"9","author":"G Navarro","year":"2018","unstructured":"Navarro G, Varani K, Reyes-Resina I, S\u00e1nchez de Medina V, Rivas-Santisteban R, S\u00e1nchez-Carnerero Callado C, Vincenzi F, Casano S, Ferreiro-Vera C, Canela EI et al (2018) Cannabigerol action at cannabinoid CB1 and CB2 receptors and at CB1-CB2 Heteroreceptor complexes. Front Pharmacol 9:632. https:\/\/doi.org\/10.3389\/fphar.2018.00632","journal-title":"Front Pharmacol"},{"key":"6_CR59","doi-asserted-by":"publisher","first-page":"422","DOI":"10.3389\/fnins.2016.00422","volume":"10","author":"J Navarro-Dorado","year":"2016","unstructured":"Navarro-Dorado J, Villalba N, Prieto D, Brera B, Mart\u00edn-Moreno AM, Tejerina T, de Ceballos ML (2016) Vascular dysfunction in a transgenic model of Alzheimer\u2019s disease: effects of CB1R and CB2R cannabinoid agonists. Front Neurosci 10:422. https:\/\/doi.org\/10.3389\/fnins.2016.00422","journal-title":"Front Neurosci"},{"key":"6_CR60","doi-asserted-by":"publisher","first-page":"29","DOI":"10.9740\/mhc.2017.01.029","volume":"7","author":"C Noel","year":"2017","unstructured":"Noel C (2017) Evidence for the use of \u201cmedical marijuana\u201d in psychiatric and neurologic disorders. Ment Health Clin 7:29\u201338. https:\/\/doi.org\/10.9740\/mhc.2017.01.029","journal-title":"Ment Health Clin"},{"key":"6_CR61","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11010-016-2733-y","volume":"418","author":"S Ojha","year":"2016","unstructured":"Ojha S, Javed H, Azimullah S, Haque ME (2016) \u03b2-Caryophyllene, a phytocannabinoid attenuates oxidative stress, neuroinflammation, glial activation, and salvages dopaminergic neurons in a rat model of Parkinson disease. Mol Cell Biochem 418:59\u201370. https:\/\/doi.org\/10.1007\/s11010-016-2733-y","journal-title":"Mol Cell Biochem"},{"key":"6_CR62","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.phrs.2016.04.004","volume":"110","author":"C Palomo-Garo","year":"2016","unstructured":"Palomo-Garo C, G\u00f3mez-G\u00e1lvez Y, Garc\u00eda C, Fern\u00e1ndez-Ruiz J (2016) Targeting the cannabinoid CB 2 receptor to attenuate the progression of motor deficits in LRRK2-transgenic mice. Pharmacol Res 110:181\u2013192. https:\/\/doi.org\/10.1016\/j.phrs.2016.04.004","journal-title":"Pharmacol Res"},{"key":"6_CR63","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.neuroscience.2017.08.042","volume":"362","author":"AC Pascual","year":"2017","unstructured":"Pascual AC, Gaveglio VL, Giusto NM, Pasquar\u00e9 SJ (2017) 2-Arachidonoylglycerol metabolism is differently modulated by oligomeric and fibrillar conformations of amyloid beta in synaptic terminals. Neuroscience 362:168\u2013180. https:\/\/doi.org\/10.1016\/j.neuroscience.2017.08.042","journal-title":"Neuroscience"},{"key":"6_CR64","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1007\/s00702-019-02021-z","volume":"126","author":"M Peball","year":"2019","unstructured":"Peball M, Werkmann M, Ellmerer P, Stolz R, Valent D, Knaus H-G, Ulmer H, Djamshidian A, Poewe W, Seppi K (2019) Nabilone for non-motor symptoms of Parkinson\u2019s disease: a randomized placebo-controlled, double-blind, parallel-group, enriched enrolment randomized withdrawal study (the NMS-nab study). J Neural Transm 126:1061\u20131072. https:\/\/doi.org\/10.1007\/s00702-019-02021-z","journal-title":"J Neural Transm"},{"key":"6_CR65","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1159\/000492221","volume":"51","author":"AR Qureshi","year":"2018","unstructured":"Qureshi AR, Rana AQ, Malik SH, Rizvi SFH, Akhter S, Vannabouathong C, Sarfraz Z, Rana R (2018) Comprehensive examination of therapies for pain in Parkinson\u2019s disease: a systematic review and meta-analysis. Neuroepidemiology 51:190\u2013206. https:\/\/doi.org\/10.1159\/000492221","journal-title":"Neuroepidemiology"},{"key":"6_CR66","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.bcp.2018.06.001","volume":"157","author":"I Reyes-Resina","year":"2018","unstructured":"Reyes-Resina I, Navarro G, Aguinaga D, Canela EI, Schoeder CT, Za\u0142uski M, Kie\u0107-Kononowicz K, Saura CA, M\u00fcller CE, Franco R (2018) Molecular and functional interaction between GPR18 and cannabinoid CB2G-protein-coupled receptors. Relevance in neurodegenerative diseases. Biochem Pharmacol 157:169\u2013179. https:\/\/doi.org\/10.1016\/j.bcp.2018.06.001","journal-title":"Biochem Pharmacol"},{"key":"6_CR500","doi-asserted-by":"publisher","unstructured":"Rojo-Bustamante E, Abellanas MA, Clavero P, Thiolat ML, Qin L, Luquin MR, Bezard E, Aymerich MS (2018) The expression of cannabinoid type 1 receptor and 2-arachidonoyl glycerol synthesizing\/degrading enzymes is altered in basal ganglia during the active phase of levodopa-induced dyskinesia. Neurobiol Dis 118:64\u201375. https:\/\/doi.org\/10.1016\/j.nbd.2018.06.019","DOI":"10.1016\/j.nbd.2018.06.019"},{"key":"6_CR67","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.neuropharm.2019.03.027","volume":"150","author":"A Ruiz-Calvo","year":"2019","unstructured":"Ruiz-Calvo A, Bajo-Gra\u00f1eras R, Maroto IB, Zian D, Grabner GF, Garc\u00eda-Taboada E, Resel E, Zechner R, Zimmermann R, Ortega-Guti\u00e9rrez S et al (2019) Astroglial monoacylglycerol lipase controls mutant huntingtin-induced damage of striatal neurons. Neuropharmacology 150:134\u2013144. https:\/\/doi.org\/10.1016\/j.neuropharm.2019.03.027","journal-title":"Neuropharmacology"},{"key":"6_CR68","doi-asserted-by":"publisher","first-page":"100385","DOI":"10.1016\/j.conctc.2019.100385","volume":"15","author":"MT Ruthirakuhan","year":"2019","unstructured":"Ruthirakuhan MT, Herrmann N, Gallagher D, Andreazza AC, Kiss A, Verhoeff NPLG, Black SE, Lanct\u00f4t KL (2019) Investigating the safety and efficacy of nabilone for the treatment of agitation in patients with moderate-to-severe Alzheimer\u2019s disease: study protocol for a cross-over randomized controlled trial. Contemporary Clin Trial Comm 15:100385. https:\/\/doi.org\/10.1016\/j.conctc.2019.100385","journal-title":"Contemporary Clin Trial Comm"},{"key":"6_CR69","doi-asserted-by":"publisher","first-page":"18r12617","DOI":"10.4088\/JCP.18r12617","volume":"80","author":"M Ruthirakuhan","year":"2019","unstructured":"Ruthirakuhan M, Lanct\u00f4t KL, Vieira D, Herrmann N (2019) Natural and synthetic cannabinoids for agitation and aggression in Alzheimer\u2019s disease. J Clin Psychiatry 80:18r12617. https:\/\/doi.org\/10.4088\/JCP.18r12617","journal-title":"J Clin Psychiatry"},{"key":"6_CR70","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1038\/sj.bjp.0707460","volume":"152","author":"E Ryberg","year":"2007","unstructured":"Ryberg E, Larsson N, Sj\u00f6gren S, Hjorth S, Hermansson N-O, Leonova J, Elebring T, Nilsson K, Drmota T, Greasley PJ (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152:1092\u20131101. https:\/\/doi.org\/10.1038\/sj.bjp.0707460","journal-title":"Br J Pharmacol"},{"key":"6_CR71","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3233\/JHD-170283","volume":"7","author":"C Saft","year":"2018","unstructured":"Saft C, von Hein SM, L\u00fccke T, Thiels C, Peball M, Djamshidian A, Heim B, Seppi K (2018) Cannabinoids for treatment of dystonia in Huntington\u2019s disease. J Huntington\u2019s Disease 7:167\u2013173. https:\/\/doi.org\/10.3233\/JHD-170283","journal-title":"J Huntington\u2019s Disease"},{"key":"6_CR72","doi-asserted-by":"publisher","first-page":"432607","DOI":"10.1155\/2011\/432607","volume":"2011","author":"AH Sam","year":"2011","unstructured":"Sam AH, Salem V, Ghatei MA (2011) Rimonabant: from RIO to ban. J Obes 2011:432607. https:\/\/doi.org\/10.1155\/2011\/432607","journal-title":"J Obes"},{"issue":"11","key":"6_CR73","doi-asserted-by":"publisher","first-page":"7719","DOI":"10.1007\/s12035-019-1637-8","volume":"56","author":"D Schubert","year":"2019","unstructured":"Schubert D, Kepchia D, Liang Z, Dargusch R, Goldberg J, Maher P (2019) Efficacy of cannabinoids in a pre-clinical drug-screening platform for Alzheimer\u2019s disease. Mol Neurobiol 56(11):7719\u20137730. https:\/\/doi.org\/10.1007\/s12035-019-1637-8","journal-title":"Mol Neurobiol"},{"key":"6_CR74","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1007\/s00429-014-0823-8","volume":"220","author":"S Sierra","year":"2015","unstructured":"Sierra S, Luquin N, Rico AJ, G\u00f3mez-Bautista V, Roda E, Dopeso-Reyes IG, V\u00e1zquez A, Mart\u00ednez-Pinilla E, Labandeira-Garc\u00eda JL, Franco R et al (2015) Detection of cannabinoid receptors CB1 and CB2 within basal ganglia output neurons in macaques: changes following experimental parkinsonism. Brain Struct Funct 220:2721\u20132738. https:\/\/doi.org\/10.1007\/s00429-014-0823-8","journal-title":"Brain Struct Funct"},{"key":"6_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mrfmmm.2017.04.001","volume":"800\u2013802","author":"O Simard","year":"2017","unstructured":"Simard O, Niavarani SR, Gaudreault V, Boissonneault G (2017) Torsional stress promotes trinucleotidic expansion in spermatids. Mutation Research\/Fundamental and Molecular Mechanisms of Mutagenesis 800\u2013802:1\u20137. https:\/\/doi.org\/10.1016\/j.mrfmmm.2017.04.001","journal-title":"Mutation Research\/Fundamental and Molecular Mechanisms of Mutagenesis"},{"key":"6_CR76","doi-asserted-by":"publisher","first-page":"9913","DOI":"10.1021\/acs.jmedchem.7b00155","volume":"60","author":"F Spinelli","year":"2017","unstructured":"Spinelli F, Capparelli E, Abate C, Colabufo NA, Contino M (2017) Perspectives of cannabinoid type 2 receptor (CB2R) ligands in neurodegenerative disorders: structure\u2013affinity relationship (SAfiR) and structure\u2013activity relationship (SAR) studies. J Med Chem 60:9913\u20139931. https:\/\/doi.org\/10.1021\/acs.jmedchem.7b00155","journal-title":"J Med Chem"},{"key":"6_CR77","doi-asserted-by":"publisher","first-page":"E50","DOI":"10.1503\/cmaj.170361","volume":"190","author":"SJ Udow","year":"2018","unstructured":"Udow SJ, Freitas ME, Fox SH, Lang AE (2018) Exacerbation of psychosis triggered by a synthetic cannabinoid in a 70-year-old woman with Parkinson disease. Can Med Assoc J 190:E50\u2013E52. https:\/\/doi.org\/10.1503\/cmaj.170361","journal-title":"Can Med Assoc J"},{"key":"6_CR78","doi-asserted-by":"publisher","first-page":"684","DOI":"10.3390\/ijms18040684","volume":"18","author":"S Valdeolivas","year":"2017","unstructured":"Valdeolivas S, Sagredo O, Delgado M, Pozo MA, Fern\u00e1ndez-Ruiz J (2017) Effects of a Sativex-like combination of Phytocannabinoids on disease progression in R6\/2 mice, an experimental model of Huntington\u2019s disease. Int J Mol Sci 18:684. https:\/\/doi.org\/10.3390\/ijms18040684","journal-title":"Int J Mol Sci"},{"key":"6_CR79","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1093\/abbs\/gmx073","volume":"49","author":"A Vall\u00e9e","year":"2017","unstructured":"Vall\u00e9e A, Lecarpentier Y, Guillevin R, Vall\u00e9e J-N (2017) Effects of cannabidiol interactions with Wnt\/\u03b2-catenin pathway and PPAR\u03b3 on oxidative stress and neuroinflammation in Alzheimer\u2019s disease. Acta Biochim Biophys Sin 49:853\u2013866. https:\/\/doi.org\/10.1093\/abbs\/gmx073","journal-title":"Acta Biochim Biophys Sin"},{"key":"6_CR80","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1126\/science.aaf7497","volume":"356","author":"ACM van Esbroeck","year":"2017","unstructured":"van Esbroeck ACM, Janssen APA, Cognetta AB, Ogasawara D, Shpak G, van der Kroeg M, Kantae V, Baggelaar MP, de Vrij FMS, Deng H et al (2017) Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474. Science 356:1084\u20131087. https:\/\/doi.org\/10.1126\/science.aaf7497","journal-title":"Science"},{"key":"6_CR81","doi-asserted-by":"publisher","first-page":"4731","DOI":"10.1007\/s12035-017-0676-2","volume":"55","author":"L Wang","year":"2018","unstructured":"Wang L, Liu B-J, Cao Y, Xu W-Q, Sun D-S, Li M-Z, Shi F-X, Li M, Tian Q, Wang J-Z et al (2018) Deletion of Type-2 cannabinoid receptor induces Alzheimer\u2019s disease-like tau pathology and memory impairment through AMPK\/GSK3\u03b2 pathway. Mol Neurobiol 55:4731\u20134744. https:\/\/doi.org\/10.1007\/s12035-017-0676-2","journal-title":"Mol Neurobiol"},{"key":"6_CR82","doi-asserted-by":"publisher","first-page":"46603","DOI":"10.18632\/oncotarget.10314","volume":"7","author":"M-L Zeissler","year":"2016","unstructured":"Zeissler M-L, Eastwood J, McCorry K, Hanemann OC, Zajicek JP, Carroll CB (2016) Delta-9-tetrahydrocannabinol protects against MPP+ toxicity in SH-SY5Y cells by restoring proteins involved in mitochondrial biogenesis. Oncotarget 7:46603\u201346614. https:\/\/doi.org\/10.18632\/oncotarget.10314","journal-title":"Oncotarget"}],"container-title":["Advances in Experimental Medicine and Biology","Cannabinoids and Neuropsychiatric Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-030-57369-0_6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T09:40:32Z","timestamp":1608198032000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-030-57369-0_6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,18]]},"ISBN":["9783030573683","9783030573690"],"references-count":83,"URL":"https:\/\/doi.org\/10.1007\/978-3-030-57369-0_6","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,18]]},"assertion":[{"value":"18 December 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}